A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

Innovation is never easy. It requires the audacity to create a new path, one where we will encounter novel obstacles that demand both resourcefulness and bold imagination. But when we stand together, ...

In a significant leap forward for neuroscience, researchers at the University of California, Santa Barbara, have successfully ...

More about Caribou Biosciences Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on CRISPR genome-editing technology. The company specializes in developing allogeneic CAR ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at ...

86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35) Vispa-cel is generally well-tolerated, allowing for administration in the outpatient ...

Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company's genome-editing ...

And I do have several favorite stocks that fit that description. My top growth stock to buy in November is one that I've ...

According to Bloomberg News, Vinay Prasad, who oversees gene therapies at the FDA, said the plans will be published in early November. He foresees the approach sparking curiosity for the next wave of ...